CJC-1295 DAC vs Tesamorelin — Growth

CJC-1295 with Drug Affinity Complex (DAC) and tesamorelin are both GHRH (growth hormone-releasing hormone) analogues that stimulate GH release through the GHRH receptor. However, they differ fundamentally in half-life engineering, clinical indication, and regulatory status. CJC-1295 DAC uses a covalent albumin-binding moiety for dramatic half-life extension; tesamorelin uses a stabilized peptide scaffold for intermediate half-life. Understanding their pharmacological distinctions informs rational GHRH analogue selection.

Molecular Profiles

CJC-1295 with DAC

CJC-1295 is a synthetic GHRH analogue with four amino acid substitutions and a Drug Affinity Complex (DAC) for albumin binding:

• Sequence: [D-Ala², Gln³⁸, Thr⁴⁸, Lys⁴⁷]-hGRF(1-29)-NH₂ + DAC moiety
• DAC: Maleimidopropionyl (MP) linker attached to Lys⁴⁷, conjugated to mercapto-PEG for albumin binding
• Molecular weight: ~3,580 Da (CJC-1295) + ~2 kDa (DAC) = ~5.5 kDa
• Half-life: ~6–8 hours (with DAC) vs ~30 minutes (without DAC)
• Receptor: GHRH receptor (GHRHR)
• Frequency: 1–2× per week (SC injection)

Tesamorelin

Tesamorelin (Egrifta) is a synthetic GHRH analogue with a transglutaminase-resistant modification:

• Sequence: [transglutaminase-resistant] hGRF(1-44)
• Modification: His¹ replaced with 3-mercaptopropionic acid (Mpa) at the N-terminus → resistance to transglutaminase-mediated degradation
• Molecular weight: ~5,136 Da
• Half-life: ~25–40 minutes
• Receptor: GHRH receptor (GHRHR)
• Frequency: 2× daily (SC injection)

Mechanism of Half-Life Extension

CJC-1295 DAC: Covalent Albumin Binding

The DAC moiety confers half-life extension through a two-step mechanism:

1. Covalent attachment: The maleimidopropionyl linker reacts with Cys³⁴ of circulating albumin, forming a stable thioether bond.
2. Renal protection: The resulting CJC-1295-albumin complex (~67 kDa) is too large for glomerular filtration, preventing renal clearance.
3. Proteolytic resistance: Albumin binding shields the peptide from proteolytic degradation.
4. GH pulsatility preserved: CJC-1295 retains pulsatile GH release despite extended half-life — a critical distinction from continuous GH infusion.

The covalent albumin binding is irreversible, meaning the peptide-albumin complex circulates for the albumin half-life (~19 days), though the GHRH activity decays over 6–8 hours as the peptide is degraded while still albumin-bound.

Tesamorelin: Transglutaminase Resistance

Tesamorelin achieves moderate half-life extension through:

1. N-terminal modification: The Mpa substitution at position 1 blocks transglutaminase-mediated crosslinking — a major degradation pathway for native GHRH.
2. Resistance to DPP-IV: The N-terminal modification also confers resistance to dipeptidyl peptidase IV degradation.
3. Intermediate stability: Half-life extended from ~3 minutes (native GHRH) to ~25–40 minutes — sufficient for twice-daily dosing.

Receptor Pharmacology

Property	CJC-1295 DAC	Tesamorelin
GHRHR affinity	High (EC₅₀ ~0.5 nM)	High (EC₅₀ ~0.3 nM)
GH release magnitude	3–5× baseline	2–4× baseline
Pulsatility	Preserved	Preserved
IGF-1 elevation	40–60% above baseline	30–50% above baseline
Somatostatin interaction	Normal	Normal

Both agents activate the physiological GH pulsatility axis — neither produces continuous GH elevation. Tesamorelin’s slightly higher GHRHR affinity translates to comparable or marginally greater GH release per dose.

Clinical Evidence

CJC-1295 DAC

Clinical data for CJC-1295 DAC are primarily from Phase I/II studies:

• Healthy volunteers: CJC-1295 DAC (30–60 µg/kg SC) produced dose-dependent GH release (peak ~35 µg/L) and sustained IGF-1 elevation above the age-matched normal range for 6+ days after a single dose.
• GH-deficient adults: Pilot studies showed restoration of IGF-1 to normal range with weekly dosing, comparable to daily GH replacement.
• Body composition: Increases in lean body mass and decreases in fat mass were observed in small studies.

Tesamorelin

Tesamorelin has extensive Phase III evidence:

EGRIFTA Phase III (HIV-associated lipodystrophy):

• Primary endpoint: Reduction in visceral adipose tissue (VAT) — tesamorelin achieved 15–20% VAT reduction over 26 weeks vs. 6% with placebo.
• Secondary endpoints: Improved waist circumference, triglycerides, and IGF-1 levels.
• FDA approval: 2010, for HIV-associated lipodystrophy with excess abdominal fat.

Post-marketing data:

• Sustained VAT reduction with continued therapy.
• IGF-1 levels remained within the age-matched normal range with appropriate dosing monitoring.
• No increase in malignancy risk with up to 52 weeks of therapy.

Clinical Applications

Application	CJC-1295 DAC	Tesamorelin
GH deficiency (adult)	Investigational	Investigational
HIV lipodystrophy	Investigational	FDA-approved
Body composition	Investigational	Approved (HIV)
Anti-aging	Investigational	Not approved
Pediatric GH deficiency	Investigational	Not approved
Short bowel syndrome	Investigational	Not approved

Dosing and Administration

Parameter	CJC-1295 DAC	Tesamorelin
Dose	30–60 µg/kg	2 mg SC
Frequency	1–2× per week	2× daily
Route	SC injection	SC injection
Titration	Dose escalation over weeks	Fixed dose
Monitoring	IGF-1, glucose	IGF-1, glucose

Tesamorelin’s twice-daily dosing (2 mg SC) is less convenient than CJC-1295 DAC’s weekly injection, though both are well-tolerated.

Safety Comparison

Effect	CJC-1295 DAC	Tesamorelin
Injection site reactions	10–20%	10–15%
Headache	10–15%	10–15%
Flushing	15–25%	5–10%
Hyperglycemia	10–15%	5–10%
GI symptoms	5–10%	5–10%
Carpal tunnel	Rare	Rare
Theoretical cancer risk	Unknown	Not demonstrated

CJC-1295 DAC’s more frequent flushing may relate to the DAC moiety’s interaction with vascular endothelium. Both agents carry theoretical concerns about IGF-1-mediated cancer risk, though no clinical signal has emerged.

Summary

CJC-1295 DAC and tesamorelin are both GHRH analogues with distinct pharmacological engineering strategies. CJC-1295 DAC uses covalent albumin binding (DAC) for 6–8 hour half-life and weekly dosing, while tesamorelin uses transglutaminase resistance for 25–40 minute half-life and twice-daily dosing. Tesamorelin has the stronger clinical evidence base (FDA-approved for HIV lipodystrophy), while CJC-1295 DAC’s pharmacokinetic convenience (weekly dosing) offers advantages for long-term GH replacement therapy. Both preserve physiological GH pulsatility, a critical distinction from continuous GH infusion. The choice depends on clinical indication, dosing preference, and regulatory availability.